Matthew Fomonyuy Yuyun1, Sandeep K Jutla1, Paulene A Quinn1, Leong L Ng1. 1. Department of Cardiovascular Sciences, University of Leicester, Leicester, UK; Leicester NIHR Biomedical Research Unit in Cardiovascular Disease, Glenfield Hospital, Leicester, UK.
Abstract
OBJECTIVE: Aldosterone is associated with increased mortality in chronic heart failure patients and correlates with adverse outcomes after an acute myocardial infarction (AMI) in smaller cohorts. We evaluated the prognostic significance of plasma aldosterone in a large cohort of post-AMI patients in relation to major adverse cardiovascular events (MACE). DESIGN: A prospective cohort study. SETTING: University Hospitals of Leicester, UK. PATIENTS: Consecutive 955 patients admitted with AMI. Plasma aldosterone levels were measured in these patients. MAIN OUTCOME MEASURES: During the 2 years follow-up, MACE which was a composite of all-cause mortality, myocardial reinfarction, and hospitalisation for heart failure as well as secondary endpoints (all-cause mortality and a combination of all-cause mortality and hospitalisation for heart failure), were ascertained. RESULTS: MACE occured in N=261, 27.3%, all-cause mortality (N=114, 11.9%) and a combination of all-cause mortality and hospitalisation for heart failure (N=176, 18.4%). Patients with MACE had significantly higher median levels of aldosterone than those without (1150.1 vs 950.4 pmol/l, p=0.0118). The multivariate adjusted HR (95% CI) for log aldosterone on MACE was 1.26 (1.01 to 1.56), p=0.041; all-cause mortality 1.60 (1.13 to 2.27), p=0.008; and combination of all-cause mortality and heart failure 1.50 (1.14 to 1.97), p=0.003. CONCLUSIONS: The prognostic significance of aldosterone for a variety of endpoints in this large cohort of post-AMI patients is not new and adds to the findings by others. The magnitude of the increase in aldosterone secretion post infarction is higher than previously believed.
OBJECTIVE: Aldosterone is associated with increased mortality in chronic heart failurepatients and correlates with adverse outcomes after an acute myocardial infarction (AMI) in smaller cohorts. We evaluated the prognostic significance of plasma aldosterone in a large cohort of post-AMI patients in relation to major adverse cardiovascular events (MACE). DESIGN: A prospective cohort study. SETTING: University Hospitals of Leicester, UK. PATIENTS: Consecutive 955 patients admitted with AMI. Plasma aldosterone levels were measured in these patients. MAIN OUTCOME MEASURES: During the 2 years follow-up, MACE which was a composite of all-cause mortality, myocardial reinfarction, and hospitalisation for heart failure as well as secondary endpoints (all-cause mortality and a combination of all-cause mortality and hospitalisation for heart failure), were ascertained. RESULTS: MACE occured in N=261, 27.3%, all-cause mortality (N=114, 11.9%) and a combination of all-cause mortality and hospitalisation for heart failure (N=176, 18.4%). Patients with MACE had significantly higher median levels of aldosterone than those without (1150.1 vs 950.4 pmol/l, p=0.0118). The multivariate adjusted HR (95% CI) for log aldosterone on MACE was 1.26 (1.01 to 1.56), p=0.041; all-cause mortality 1.60 (1.13 to 2.27), p=0.008; and combination of all-cause mortality and heart failure 1.50 (1.14 to 1.97), p=0.003. CONCLUSIONS: The prognostic significance of aldosterone for a variety of endpoints in this large cohort of post-AMI patients is not new and adds to the findings by others. The magnitude of the increase in aldosterone secretion post infarction is higher than previously believed.
Entities:
Keywords:
Heart Failure; Myocardial Ischaemia And Infarction (IHD)
Authors: Karl T Weber; Yao Sun; Linus A Wodi; Ahmad Munir; Eiman Jahangir; Robert A Ahokas; Ivan C Gerling; Arnold E Postlethwaite; Kenneth J Warrington Journal: J Renin Angiotensin Aldosterone Syst Date: 2003-09 Impact factor: 1.636
Authors: Andreas Tomaschitz; Winfried Maerz; Stefan Pilz; Eberhard Ritz; Hubert Scharnagl; Wilfried Renner; Bernhard O Boehm; Astrid Fahrleitner-Pammer; Gisela Weihrauch; Harald Dobnig Journal: J Am Coll Cardiol Date: 2010-05-11 Impact factor: 24.094
Authors: Andreas Tomaschitz; Stefan Pilz; Eberhard Ritz; Andreas Meinitzer; Bernhard O Boehm; Winfried März Journal: Eur Heart J Date: 2010-03-02 Impact factor: 29.983
Authors: Fabrice Ivanes; Sophie Susen; Frédéric Mouquet; Pascal Pigny; François Cuilleret; Karine Sautière; Jean-Philippe Collet; Farzin Beygui; Bernadette Hennache; Pierre Vladimir Ennezat; Françis Juthier; Florence Richard; Jean Dallongeville; Marieke A Hillaert; Pieter A Doevendans; Brigitte Jude; Michel Bertrand; Gilles Montalescot; Eric Van Belle Journal: Eur Heart J Date: 2011-06-30 Impact factor: 29.983
Authors: J S Silvestre; V Robert; C Heymes; B Aupetit-Faisant; C Mouas; J M Moalic; B Swynghedauw; C Delcayre Journal: J Biol Chem Date: 1998-02-27 Impact factor: 5.157